Longitude gets some latitude in 'brutal' climate as it builds new $375m fund
This article was originally published in Scrip
Longitude Capital has collected $331.6 million from limited partners for an anticipated $375 million venture capital fund in a fundraising environment that managing director Patrick Enright described only as "brutal".
You may also be interested in...
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.